Dr.

Michael Epitropoulos' Position of Chief Scientific Officer at HAPInss Brands

LLC

In the newly formed position of Chief Scientific Officer, Dr. Epitropoulos will lead evidenced-based
research efforts across the entire HAPInss Brands portfolio of products.

Greenwood, IN, September 23, 2020 --(PR.com)-- HAPInss Brands (the “Company”) today announced
the addition of Dr. Michael Epitropoulos as the Company’s new Chief Scientific Officer. Dr.
Epitropoulos brings over 35 years of medical affairs, communications, and research experience in
nutrition, healthcare, and the consumer goods industries.

Dr. Epitropoulos holds a Doctorate of Chiropractic degree as well as a Doctorate of Applied Clinical
Nutrition degree. His training is extensive including medicine as well as specialized training in Applied
Kinesiology, Contact Reflex Analysis, and Energy Medicine. He has been a contributing writer to 2
books as well as several natural health publications and taught clinical nutrition at colleges in North
Carolina, Michigan and Florida. He speaks all over the country and is a featured speaker at Chiropractic
Conventions teaching Doctors how to incorporate Natural Medicine in their practices. He has hosted
popular radio shows on natural healing in both Florida and Michigan. He has been practicing Chiropractic
and Functional Medicine for well over 35 years and currently is in private practice in Ormond Beach
Florida where people come to him from all over the U.S. because of his work in Natural Medicine.

Dr. Epitropoulos also brings his “Nucleotide Science Technology” and formulations now exclusive to
HAPInss Brands. He has done over 17 years of extensive research in the area of Nucleotide Science and
continues to do clinical studies with Nucleotide Supplementation in his office.

Dr. Epitropoulos position at HAPInss Brands will allow him to expand and contribute to consumer
understanding of gut-brain health, how nucleotide science works, and the many benefits CBD may
provide. He will help lead it’s newly formed Scientific Advisory Board with an existing team of experts
that includes other doctors, specialists, nutritionists, product formulators, and manufacturing experts who
together have helped develop a number of health and wellness products in the US and abroad.

“Dr. Epitropoulos has a long history of helping consumer product companies share a clear, and
scientifically backed, narrative around product benefits. Gut-Health and CBD are performance categories,
and the most successful brands will be those that understand and are able to clearly communicate why
their products work. There are few researchers of Dr. Epitropoulos’ caliber in the gut-health and CBD
industries today, and we believe he will play an invaluable role not only for HAPInss Brands, but as a
thought leader within the industry,” stated Robert Oblon, Founder and CEO.

“I have been intrigued by gut-health for years and saw a huge opportunity to apply my scientific and
consumer products background for HAPInss Brands to help validate and articulate how their products
may help people live better lives,” stated Epitropoulos. “I also believe scientifically-based education is
vital to the future of the industry, and HAPInss Brands has focused their business processes in a way that
ensures science is at the center of their product development DNA.”

Page 1/3
PR.com Press Release Distribution Terms of Use
About HAPInss Brands™ and Amplifei International™

HAPInss Brands™ (https://hapinss.com/) is a technology company providing people with the latest
technological advances specific to amplifying the state of wellbeing, also known as happiness.

Amplifei International™ (https://amplifei.com/) is a health and wellness lifestyle company serving

freelance entrepreneurs in the Gig Economy.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
AmpLIFEi International
Troy Dooly
1 (833) 833-2683
Contact via Email
Amplifei.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/821834

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use